BBA
RXII

BLB&B Advisors’s GALENA BIOPHARMA INC COM RXII Stock Holding History

BLB&B Advisors’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,000
Closed -$23K – 258
2013
Q3 		$23K Buy
+10,000
New +$23K 0.01% 241

Other funds holding RXII

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

BLB&B Advisors's RXII Position: Q4 2013 in Review

BLB&B Advisors sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2013, closing a stake of 10,000 shares — an estimated $23K sold.

BLB&B Advisors first reported a position in RXII in Q3 2013 and held it in 1 quarter. The position peaked at $23K in Q3 2013. 76 funds tracked by Wall St. Rank hold RXII as of Q4 2013.

  • BLB&B Advisors reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2013 after selling out during the quarter.
  • BLB&B Advisors sold 10,000 GALENA BIOPHARMA INC COM shares in Q4 2013, an estimated $23K.
  • BLB&B Advisors first reported a position in GALENA BIOPHARMA INC COM in Q3 2013 and held it in 1 quarter.
  • BLB&B Advisors's GALENA BIOPHARMA INC COM position peaked at $23K in Q3 2013.
  • 76 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2013.

Based on BLB&B Advisors's 13F filing for Q4 2013, filed 17 Jan 2014.